Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Editas Medicine revenue
Editas Medicine's revenue is $32.3 million.
What is Editas Medicine's revenue?
- Editas Medicine's revenue growth from 2015 to 2024 is 1,883.67%.
- Editas Medicine has 133 employees, and the revenue per employee ratio is $242,962.
- Editas Medicine's peak quarterly revenue was $62.8M in 2020(q3).
- Editas Medicine peak revenue was $90.7M in 2020.
- Editas Medicine annual revenue for 2023 was 78.1M, 296.32% growth from 2022.
- Editas Medicine annual revenue for 2024 was 32.3M, -58.64% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Editas Medicine historical revenue
Editas Medicine's peak revenue was $90.7M in 2020. The peak quarterly revenue was $62.8M in 2020(q3).
Editas Medicine's revenue increased from $1.6m in 2015 to $32.3M currently. That's a 1,883.67% change in annual revenue.
Editas Medicine annual revenue
Editas Medicine annual revenue over time
| Fiscal year / year | Editas Medicine revenue |
|---|---|
| 2015 | $1.6M |
| 2016 | $6.1M |
| 2017 | $13.7M |
| 2018 | $31.9M |
| 2019 | $20.5M |
| 2020 | $90.7M |
| 2021 | $25.5M |
| 2022 | $19.7M |
| 2023 | $78.1M |
| 2024 | $32.3M |
How accurately did Editas Medicine's revenue projections match actual performance?
Editas Medicine annual growth
Editas Medicine saw the greatest revenue growth in 2020, when revenue increased by 341.93%.
Editas Medicine had the lowest revenue growth in 2021, when revenue changed by -71.85%.
Editas Medicine annual growth rate over time
| Year | Editas Medicine growth |
|---|---|
| 2016 | 272%↑ |
| 2017 | 127%↑ |
| 2018 | 133%↑ |
| 2019 | -36%↓ |
| 2020 | 342%↑ |
| 2021 | -72%↓ |
| 2022 | -23%↓ |
| 2023 | 296%↑ |
| 2024 | -59%↓ |
Editas Medicine quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Editas Medicine quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2015 | - | - | - | $792,000 |
| 2016 | $805,000 | $3.4M | $962,000 | $898,000 |
| 2017 | $682,000 | $3.1M | $6.3M | $3.7M |
| 2018 | $3.9M | $7.4M | $14.5M | $6.1M |
| 2019 | $2.1M | $2.3M | $3.8M | $12.3M |
| 2020 | $5.7M | $10.7M | $62.8M | $11.4M |
| 2021 | $6.5M | $379,000 | $6.2M | $12.5M |
| 2022 | $6.8M | $6.4M | $42,000 | $6.5M |
| 2023 | $9.9M | $2.9M | $5.3M | $60.0M |
| 2024 | $1.1M | $513,000 | $61,000 | $30.6M |
Editas Medicine jobs nearby
Do you work at Editas Medicine?
Did Editas Medicine meet its revenue projections?
Editas Medicine financial information
| CEO | Katrine Bosley |
| Company Type | Public |
| Employees Number | 133 |
| Date Founded | 2013 |
| Headquarters | Cambridge, Massachusetts |
| Number of Locations | 2 |
| Revenue | $32.3M |
| Net Income | -$220,432,000 |
| PE Ratio | -4.18 |
| Market Capitalization | $990.6M |
| Total Assets | $514,321,000 |
| Ticker | EDIT |
Editas Medicine jobs you might like
Editas Medicine financing
Editas Medicine received early financing of $43.0M on 2013-11-25.
| Series | Round size | Date |
|---|---|---|
| Series A | $43M | 11/2013 |
| Undisclosed | $47M | 05/2015 |
| Series B | $120M | 08/2015 |
| Post Ipo Equity | $215.6M | 06/2020 |
| Post Ipo Equity | $231M | 01/2021 |
Editas Medicine investors
| Investors | Security type |
|---|---|
| Polaris Partners | Series A |
| Partners Innovation Fund | Series A |
| Third Rock Ventures | Series A |
| Flagship Pioneering Inc | Series A |
| Juno Therapeutics Inc | Undisclosed |
| Polaris Partners | Series B |
| EcoR1 Capital LLC | Series B |
| Deerfield | Series B |
| Omega Funds | Series B |
| FMR Co. | Series B |
| Khosla Ventures | Series B |
| Viking Global Investors | Series B |
| Jennison Associates | Series B |
| Alexandria Venture | Series B |
| Third Rock Ventures | Series B |
| Boris Nikolic | Series B |
| GV | Series B |
| T. Rowe Price Group, Inc. | Series B |
| Casdin Capital | Series B |
| Flagship Pioneering Inc | Series B |
Editas Medicine competitors
Editas Medicine's top competitor, Merck, earned an annual revenue of $64.2B.
Editas Medicine's smallest competitor is Nektar Therapeutics with revenue of $98.4M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Merck | $90,328 | $64.2B | 74,000 | 1,494 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 907 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 278 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Regeneron | $85,589 | $14.2B | 9,123 | 355 |
| Zoetis | $87,092 | $9.3B | 11,300 | 227 |
| Moderna | $81,825 | $3.2B | 2,500 | 8 |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Acorda Therapeutics | $97,279 | $117.6M | 344 | - |
| Quidel | $71,489 | $1.7B | 1,500 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Editas Medicine highest paying jobs
Zippia gives an in-depth look into the details of Editas Medicine, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Editas Medicine. The employee data is based on information from people who have self-reported their past or current employments at Editas Medicine. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Editas Medicine. The data presented on this page does not represent the view of Editas Medicine and its employees or that of Zippia.
Editas Medicine may also be known as or be related to EDITAS MEDICINE INC., Editas Medicine, Editas Medicine Inc and Editas Medicine, Inc.